Experimental combo for Hard-to-Treat cancers shows early promise but study halted
Disease control
Terminated
This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC